Aurora Cannabis Stock Hits 52-Week Low: What Investors Should Know

Aurora Cannabis stock continues to fall, hitting a yearly bottom last week. So what should investors do now?

| More on:
Cannabis smoke

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Aurora Cannabis (TSX:ACB) shares hit a 52-week low last week as pot stocks continue to suffer. The once-great marijuana producer looks less and less promising these days. So what’s going on?

Here, I’m going to dig in and see whether Aurora Cannabis shares are indeed a bad buy or merely need more time to come off this bad trip.

The stock’s recent rise and fall

Cannabis stocks in general got a bit of a boost earlier this spring, after the U.S. House of Representatives sent through a new federal legalization bill. While the bill isn’t likely to pass the Senate, it was nice to see lawmakers moving again.

From this, Aurora Cannabis and its peers got a bit of a boost. But all those gains were quickly wiped away after investors realized the news would be short-lived. And that became especially true for Edmonton-based Aurora, whose Canadian competitors are focused on taking action to turn a profit ASAP. Meanwhile, Aurora seems to be more talk than action.

What Aurora Cannabis has been up to

Earnings for Aurora Cannabis during the last quarter were rough, to say the least. Total revenue came in 10% lower than the year before, and the only reason EBITDA losses dropped to $9 million from $80 million between 2020 and 2022 was because of cost savings.

It doesn’t help that the company has been on an acquisition spree, diluting shareholders’ investments in the process. I’d hope that Aurora would stop making acquisitions and instead take a break to focus on profit. Unfortunately, shares continue to struggle after the company announced the acquisition of TerraFarma, parent of Thrive Cannabis. Today, the stock seems stuck under the weight of Aurora’s balance sheet — one that isn’t backed up by major partners like its peers enjoy.

Is it all bad news?

It’s possible the Thrive deal will help in the long term. Thrive has been EBITDA-positive for 12 months, with innovative, award-winning products that could indeed help revive Aurora’s shares. The deal is expected to close in the fourth quarter of 2022 and will take time to pan out if it occurs. So until then, I’m waiting for Aurora Cannabis to make more moves toward immediate profitability.

What current Aurora Cannabis investors should do

Here’s the big question. And it’s certainly not an easy one to answer. It seems clear that Aurora shares have more room to fall. However, if you’re already an investor in Aurora Cannabis, you probably bought cannabis stocks in the first place because you were thinking long-term.

If you’re willing to wait until the U.S. legalizes pot everywhere (which of course could take years), that’s what I would recommend.

However, if you’re tired of seeing red, I get it. It’s perfectly fine to cut your losses and invest the proceeds into something more stable, especially in this volatile market.

Shares of Aurora Cannabis stock are down 43% year to date and 64% in the last year.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Amy Legate-Wolfe has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »